Management of nonmelanoma skin cancer in 2007

Nature Clinical Practice Oncology

Volumn 4, Issue 8, 2007, Pages 462-469

  Neville, Julie A ^a   Welch, Erin ^b   Leffell, David J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; ETRETIN; FLUOROURACIL; IMIQUIMOD; INTERFERON; LIQUID NITROGEN; PARACETAMOL; RETINOID;

ACTINIC KERATOSIS; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APPLICATION SITE PAIN; ARTHRALGIA; BASAL CELL CARCINOMA; CARCINOMA IN SITU; CAUTERIZATION; CHEILITIS; CHEMOSURGERY; CLINICAL EFFECTIVENESS; CRYOSURGERY; DEPIGMENTATION; ERYTHEMA; FATIGUE; FEVER; HAIR LOSS; HEADACHE; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; IMPETIGO; IONIZING RADIATION; LOW DRUG DOSE; LYMPHADENOPATHY; MYALGIA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PRURITUS; RADIATION INJURY; RADIATION NECROSIS; REVIEW; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN CANCER; SKIN IRRITATION; SQUAMOUS CELL CARCINOMA; TELANGIECTASIA; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSIS;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; NEOPLASM INVASIVENESS; SKIN NEOPLASMS;

EID: 34548567532     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0883     Document Type: Review

References (47)

1. American Cancer Society (online 20 November 2006) What is nonmelanoma skin cancer? [http://www.cancer.org/docroot/CRI/content/ CRI_2_2_1X_How_many_people_get_nonmelanoma_skin_cancer_51.asp? sitearea=] (accessed 1 December 2006)
2. Housman TS et al. (2003) Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 46: 425-429.
3. Chen J et al. (2001) Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 27: 1035-1038
4. Martinez JC and Otley CC (2001) The management of melanoma and nonmelanoma skin cancer: A review for the primary care physician. Mayo Clin Proc 76: 1253-1265
5. Nguyen T and Ho D (2002) Nonmelanoma skin cancer. Curr Treat Options Oncol 3: 193-203
6. Abide JM et al. (1984) The meaning of surgical margins. Plast Reconstr Surg 73: 492-497
7. Shriner DL et al. (1998) Mohs micrographic surgery. J Am Acad Dermatol 39: 79-97
8. Randle HW (1996) Basal cell carcinoma: Identification and treatment of the high-risk patient. Dermatol Surg 22: 255-261
9. Thissen M et al. (1999) A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 135 1177-1183
10. Smeets N et al. (2004) Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: Randomized controlled trial. Lancet 364: 1766-1772
11. Essers B et al. (2006) Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Arch Dermatol 142: 187-194
12. Rowe DE et al. (1992) Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: Implications for treatment modality selection. J Am Acad Dermatol 26: 976-990
13. Voss N and Kim-Sing C (1998) Radiotherapy in the treatment of dermatologic malignancies. Dermatol Clin 16: 313-320
14. Silverman MK et al. (1992) Recurrence rates of treated basal cell carcinomas - part 4: X-ray therapy. J Dermatol Surg Oncol 18 549-554
15. Kuflik EG (1994) Cryosurgery updated. J Am Acad Dermatol 31: 925-944
16. Kuflik EG (1991) The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 24: 1002-1004
17. An KP and Ratner D (2001) Surgical management of cutaneous malignancies. Clin Dermatol 19: 305-320
18. Rowe DE et al. (1989) Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: Implications for patient follow-up. J Dermatol Surg Oncol 15: 315-326
19. Sheridan A and Dawber R (2000) Curettage, electrosurgery, and skin cancer. Australas J Dermatol 41: 19-30
20. Kopf AW et al. (1977) Curettage and electrodesiccation treatment of basal cell carcinomas. Arch Dermatol 133: 439-443
21. Chakrabarty A and Geisse J (2004) Medical therapies for non-melanoma skin cancer. Clin Dermatol 22: 183-188
22. Goette DK (1981) Topical chemotherapy with 5-fluorouracil. J Am Acad Dermatol 6: 633-649
23. Acarturk TO and Edington H (2005) Nonmelanoma skin cancer. Clin Plastic Surg 32: 237-248
24. Dillaha J et al. (1983) Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol 119: 774-783
25. Mohs FE et al. (1978) Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol 114: 1021-1022
26. Berman B (2002) Imiquimod: A new immune response modulator for the treatment of external genital warts and other diseases in dermatology. Int J Dermatol 41 (Suppl 1): S7-S11
27. Meyer T et al. (2003) Induction of apoptosis by toll-like receptor 7 agonist in tissue cultures. Br J Dermatol 149 (Suppl 66): S9-S14
28. Sullivan TP et al. (2003) Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg 29: 1181-1186
29. Marks R et al. (2001) Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 44: 807-813
30. US Food and Drug Administration (online 14 July 2004) Aldara (imiquimod) 5% cream. [http://www.fda.gov/cder/foi/label/2004/20723s016lbl.pdf (accessed 1 December 2006)
31. Shumack S et al. (2002) Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: Comparison of dosing regimens. Arch Dermatol 138: 1165-1171
32. Bianchi L et al. (2003) Superficial and nodular basal cell carcinoma treated with an immune response modulator: A report of seven patients. Clin Exp Dermatol 28 (Suppl 1): S24-S26
33. Beutner KR et al. (1999) Therapeutic response of basal cell carcinoma to the immune response modified imiquimod 5% cream. J Am Acad Dermatol 42: 1000-1007
34. Spencer JM (2006) Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg 32: 631-69
35. Wu JK et al. (2006) An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol 47: 46-48
36. Mackenzie-Wood A et al. (2001) Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 44: 462-470
37. Orengo I et al. (2002) Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: A case report. J Am Acad Dermatol 47 (Suppl): S225-S228
38. Schroeder TL and Sengelmann RD (2002) Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 46: 545-548
39. Marmur ES et al. (2004) A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 30 264-271
40. Sziemies R et al. (2005) Photodynamic therapy of non-melanoma skin cancer. Acta Derm Venereol 85: 483-490
41. Rhodes LE et al. (2004) Photodynamic therapy using topical methyl aminolevulinate vs. surgery for nodular basal cell carcinoma. Arch Dermatol 4: 17-23
42. Salim A et al. (2003) Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 148: 539-543
43. Morton CA et al. (2001) Photodynamic therapy for large or multiple patches of Bowen's disease and basal cell carcinoma. Arch Dermatol 137: 319-324
44. Niles RM (2000) Recent advances in the use of vitamin A (retinoids) in prevention and treatment of cancer. Nutrition 16: 1084-1089
45. Otley CC et al. (2006) Chemoprevention of nonmelanoma skin cancer with systemic retinoids: Practical dosing and management of adverse effects. Dermatol Surg 32: 562-568
46. Bavnick JN et al. (1995) Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study. J Clin Oncol 13: 1933-1938
47. DeSevaux RG et al. (2003) Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: Clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 49: 407-412